Biosig Technologies (NASDAQ:STEX) Chairman Buys $49,500.00 in Stock

Biosig Technologies, Inc. (NASDAQ:STEX) Chairman Morgan Lee Lekstrom purchased 50,000 shares of the business’s stock in a transaction on Friday, June 12th. The shares were acquired at an average price of $0.99 per share, with a total value of $49,500.00. Following the completion of the transaction, the chairman owned 359,500 shares of the company’s stock, valued at approximately $355,905. This trade represents a 16.16% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Morgan Lee Lekstrom also recently made the following trade(s):

• On Thursday, May 28th, Morgan Lee Lekstrom purchased 34,000 shares of Biosig Technologies stock. The shares were acquired at an average price of $1.47 per share, with a total value of $49,980.00.
• On Thursday, May 21st, Morgan Lee Lekstrom purchased 147,000 shares of Biosig Technologies stock. The shares were acquired at an average price of $1.04 per share, with a total value of $152,880.00.
• On Tuesday, April 14th, Morgan Lee Lekstrom sold 12,759 shares of Biosig Technologies stock. The shares were sold at an average price of $1.07, for a total value of $13,652.13.

Biosig Technologies Stock Performance

NASDAQ:STEX opened at $0.93 on Thursday. The company’s 50 day moving average is $1.06. The stock has a market capitalization of $169.56 million, a price-to-earnings ratio of -0.10 and a beta of 1.85. Biosig Technologies, Inc. has a fifty-two week low of $0.70 and a fifty-two week high of $14.11.

Biosig Technologies (NASDAQ:STEX) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.27) EPS for the quarter.

Analysts Set New Price Targets

A number of analysts recently commented on STEX shares. Needham & Company LLC dropped their price target on Biosig Technologies from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, May 21st. Weiss Ratings upgraded shares of Biosig Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. Finally, Wall Street Zen lowered shares of Biosig Technologies from a “hold” rating to a “strong sell” rating in a report on Sunday, April 5th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $8.00.

Biosig Technologies Company Profile

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.